36 results on '"Harris, Reuben S."'
Search Results
2. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
- Author
-
Caswell, Deborah R., Gui, Philippe, Mayekar, Manasi K., Law, Emily K., Pich, Oriol, Bailey, Chris, Boumelha, Jesse, Kerr, D. Lucas, Blakely, Collin M., Manabe, Tadashi, Martinez-Ruiz, Carlos, Bakker, Bjorn, De Dios Palomino Villcas, Juan, I. Vokes, Natalie, Dietzen, Michelle, Angelova, Mihaela, Gini, Beatrice, Tamaki, Whitney, Allegakoen, Paul, Wu, Wei, Humpton, Timothy J., Hill, William, Tomaschko, Mona, Lu, Wei-Ting, Haderk, Franziska, Al Bakir, Maise, Nagano, Ai, Gimeno-Valiente, Francisco, de Carné Trécesson, Sophie, Vendramin, Roberto, Barbè, Vittorio, Mugabo, Miriam, Weeden, Clare E., Rowan, Andrew, McCoach, Caroline E., Almeida, Bruna, Green, Mary, Gomez, Carlos, Nanjo, Shigeki, Barbosa, Dora, Moore, Chris, Przewrocka, Joanna, Black, James R. M., Grönroos, Eva, Suarez-Bonnet, Alejandro, Priestnall, Simon L., Zverev, Caroline, Lighterness, Scott, Cormack, James, Olivas, Victor, Cech, Lauren, Andrews, Trisha, Rule, Brandon, Jiao, Yuwei, Zhang, Xinzhu, Ashford, Paul, Durfee, Cameron, Venkatesan, Subramanian, Temiz, Nuri Alpay, Tan, Lisa, Larson, Lindsay K., Argyris, Prokopios P., Brown, William L., Yu, Elizabeth A., Rotow, Julia K., Guha, Udayan, Roper, Nitin, Yu, Johnny, Vogel, Rachel I., Thomas, Nicholas J., Marra, Antonio, Selenica, Pier, Yu, Helena, Bakhoum, Samuel F., Chew, Su Kit, Reis-Filho, Jorge S., Jamal-Hanjani, Mariam, Vousden, Karen H., McGranahan, Nicholas, Van Allen, Eliezer M., Kanu, Nnennaya, Harris, Reuben S., Downward, Julian, Bivona, Trever G., and Swanton, Charles
- Abstract
In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3Bexpression in EGFR mutant (EGFRmut) non-small-cell lung cancer (NSCLC) mouse models constrained tumorigenesis, while A3Bexpression in tumors treated with EGFR-targeted cancer therapy was associated with treatment resistance. Analyses of human NSCLC models treated with EGFR-targeted therapy showed upregulation of A3B and revealed therapy-induced activation of nuclear factor kappa B (NF-κB) as an inducer of A3Bexpression. Significantly reduced viability was observed with A3B deficiency, and A3B was required for the enrichment of APOBEC mutation signatures, in targeted therapy-treated human NSCLC preclinical models. Upregulation of A3Bwas confirmed in patients with NSCLC treated with EGFR-targeted therapy. This study uncovers the multifaceted roles of A3B in NSCLC and identifies A3B as a potential target for more durable responses to targeted cancer therapy.
- Published
- 2024
- Full Text
- View/download PDF
3. APOBEC3B regulates R-loops and promotes transcription-associated mutagenesis in cancer
- Author
-
McCann, Jennifer L., Cristini, Agnese, Law, Emily K., Lee, Seo Yun, Tellier, Michael, Carpenter, Michael A., Beghè, Chiara, Kim, Jae Jin, Sanchez, Anthony, Jarvis, Matthew C., Stefanovska, Bojana, Temiz, Nuri A., Bergstrom, Erik N., Salamango, Daniel J., Brown, Margaret R., Murphy, Shona, Alexandrov, Ludmil B., Miller, Kyle M., Gromak, Natalia, and Harris, Reuben S.
- Abstract
The single-stranded DNA cytosine-to-uracil deaminase APOBEC3B is an antiviral protein implicated in cancer. However, its substrates in cells are not fully delineated. Here APOBEC3B proteomics reveal interactions with a surprising number of R-loop factors. Biochemical experiments show APOBEC3B binding to R-loops in cells and in vitro. Genetic experiments demonstrate R-loop increases in cells lacking APOBEC3B and decreases in cells overexpressing APOBEC3B. Genome-wide analyses show major changes in the overall landscape of physiological and stimulus-induced R-loops with thousands of differentially altered regions, as well as binding of APOBEC3B to many of these sites. APOBEC3 mutagenesis impacts genes overexpressed in tumors and splice factor mutant tumors preferentially, and APOBEC3-attributed kataegis are enriched in RTCW motifs consistent with APOBEC3B deamination. Taken together with the fact that APOBEC3B binds single-stranded DNA and RNA and preferentially deaminates DNA, these results support a mechanism in which APOBEC3B regulates R-loops and contributes to R-loop mutagenesis in cancer.
- Published
- 2023
- Full Text
- View/download PDF
4. Induction of APOBEC3-mediated genomic damage in urothelium implicates BK polyomavirus (BKPyV) as a hit-and-run driver for bladder cancer
- Author
-
Baker, Simon C., Mason, Andrew S., Slip, Raphael G., Skinner, Katie T., Macdonald, Andrew, Masood, Omar, Harris, Reuben S., Fenton, Tim R., Periyasamy, Manikandan, Ali, Simak, and Southgate, Jennifer
- Abstract
Limited understanding of bladder cancer aetiopathology hampers progress in reducing incidence. Mutational signatures show the anti-viral apolipoprotein B mRNA editing enzyme catalytic polypeptide (APOBEC) enzymes are responsible for the preponderance of mutations in bladder tumour genomes, but no causative viral agent has been identified. BK polyomavirus (BKPyV) is a common childhood infection that remains latent in the adult kidney, where reactivation leads to viruria. This study provides missing mechanistic evidence linking reactivated BKPyV-infection to bladder cancer risk. We used a mitotically-quiescent, functionally-differentiated model of normal human urothelium to examine BKPyV-infection. BKPyV-infection led to significantly elevated APOBEC3A and APOBEC3B protein, increased deaminase activity and greater numbers of apurinic/apyrimidinic sites in the host urothelial genome. BKPyV Large T antigen (LT-Ag) stimulated re-entry from G0 into the cell cycle through inhibition of retinoblastoma protein and activation of EZH2, E2F1 and FOXM1, with cells arresting in G2. The single-stranded DNA displacement loops formed in urothelial cells during BKPyV-infection interacted with LT-Ag to provide a substrate for APOBEC3-activity. Addition of interferon gamma (IFNγ) to infected urothelium suppressed expression of the viral genome. These results support reactivated BKPyV infections in adults as a risk factor for bladder cancer in immune-insufficient populations.
- Published
- 2022
- Full Text
- View/download PDF
5. Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA
- Author
-
Bergstrom, Erik N., Luebeck, Jens, Petljak, Mia, Khandekar, Azhar, Barnes, Mark, Zhang, Tongwu, Steele, Christopher D., Pillay, Nischalan, Landi, Maria Teresa, Bafna, Vineet, Mischel, Paul S., Harris, Reuben S., and Alexandrov, Ludmil B.
- Abstract
Clustered somatic mutations are common in cancer genomes and previous analyses reveal several types of clustered single-base substitutions, which include doublet- and multi-base substitutions1–5, diffuse hypermutation termed omikli6, and longer strand-coordinated events termed kataegis3,7–9. Here we provide a comprehensive characterization of clustered substitutions and clustered small insertions and deletions (indels) across 2,583 whole-genome-sequenced cancers from 30 types of cancer10. Clustered mutations were highly enriched in driver genes and associated with differential gene expression and changes in overall survival. Several distinct mutational processes gave rise to clustered indels, including signatures that were enriched in tobacco smokers and homologous-recombination-deficient cancers. Doublet-base substitutions were caused by at least 12 mutational processes, whereas most multi-base substitutions were generated by either tobacco smoking or exposure to ultraviolet light. Omikli events, which have previously been attributed to APOBEC3 activity6, accounted for a large proportion of clustered substitutions; however, only 16.2% of omikli matched APOBEC3 patterns. Kataegis was generated by multiple mutational processes, and 76.1% of all kataegic events exhibited mutational patterns that are associated with the activation-induced deaminase (AID) and APOBEC3 family of deaminases. Co-occurrence of APOBEC3 kataegis and extrachromosomal DNA (ecDNA), termed kyklonas (Greek for cyclone), was found in 31% of samples with ecDNA. Multiple distinct kyklonic events were observed on most mutated ecDNA. ecDNA containing known cancer genes exhibited both positive selection and kyklonic hypermutation. Our results reveal the diversity of clustered mutational processes in human cancer and the role of APOBEC3 in recurrently mutating and fuelling the evolution of ecDNA.
- Published
- 2022
- Full Text
- View/download PDF
6. Optimization and applications of a compact stem-loop DNA aptamer targeting SARS-CoV-2 nucleocapsid protein
- Author
-
Esler, Morgan, Belica, Christopher, Moghadasi, Arad, Shi, Ke, Wyllie, Mackenzie, Harki, Daniel A., Harris, Reuben S., and Aihara, Hideki
- Published
- 2024
- Full Text
- View/download PDF
7. A high-throughput cell-based screening method for Zika virus protease inhibitors discovery
- Author
-
Anindita, Paulina Duhita, Otsuka, Yuka, Lattmann, Simon, Ngo, Khac Huy, Liew, Chong Wai, Kang, CongBao, Harris, Reuben S., Scampavia, Louis, Spicer, Timothy P., and Luo, Dahai
- Abstract
Zika virus (ZIKV) continues to pose a significant global public health threat, with recurring regional outbreaks and potential for pandemic spread. Despite often being asymptomatic, ZIKV infections can have severe consequences, including neurological disorders and congenital abnormalities. Unfortunately, there are currently no approved vaccines or antiviral drugs for the prevention or treatment of ZIKV. One promising target for drug development is the ZIKV NS2B-NS3 protease due to its crucial role in the virus life cycle. In this study, we established a cell-based ZIKV protease inhibition assay designed for high-throughput screening (HTS). Our assay relies on the ZIKV protease's ability to cleave a cyclised firefly luciferase fused to a natural cleavage sequence between NS2B and NS3 protease within living cells. We evaluated the performance of our assay in HTS setting using the pharmacologic controls (JNJ-40418677 and MK-591) and by screening a Library of Pharmacologically Active Compounds (LOPAC). The results confirmed the feasibility of our assay for compound library screening to identify potential ZIKV protease inhibitors.
- Published
- 2024
- Full Text
- View/download PDF
8. SARS-CoV-2 Mproinhibitor identification using a cellular gain-of-signal assay for high-throughput screening
- Author
-
Delgado, Renee, Vishwakarma, Jyoti, Moghadasi, Seyed Arad, Otsuka, Yuka, Shumate, Justin, Cuell, Ashley, Tansiongco, Megan, Cooley, Christina B., Chen, Yanjun, Dabrowska, Agnieszka, Basu, Rahul, Anindita, Paulina Duhita, Luo, Dahai, Dosa, Peter I., Harki, Daniel A., Bannister, Thomas, Scampavia, Louis, Spicer, Timothy P., and Harris, Reuben S.
- Abstract
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2, SARS2) is responsible for the COVID-19 pandemic and infections that continue to affect the lives of millions of people worldwide, especially those who are older and/or immunocompromised. The SARS2 main protease enzyme, Mpro(also called 3C-like protease, 3CLpro), is a bona fidedrug target as evidenced by potent inhibition with nirmatrelvir and ensitrelvir, the active components of the drugs Paxlovid and Xocova, respectively. However, the existence of nirmatrelvir and ensitrelvir-resistant isolates underscores the need to develop next-generation drugs with different resistance profiles and/or distinct mechanisms of action. Here, we report the results of a high-throughput screen of 649,568 compounds using a cellular gain-of-signal assay. In this assay, Mproinhibits expression of a luciferase reporter, and 8,777 small molecules were considered hits by causing a gain in luciferase activity 3x SD above the sample field activity (6.8% gain-of-signal relative to 100 µM GC376). Single concentration and dose-response gain-of-signal experiments confirmed 3,522/8,762 compounds as candidate inhibitors. In parallel, all initial high-throughput screening hits were tested in a peptide cleavage assay with purified Mproand only 39/8,762 showed inhibition. Importantly, 19/39 compounds (49%) re-tested positive in both SARS2 assays, including two previously reported Mproinhibitors, demonstrating the efficacy of the overall screening strategy. This approach led to the rediscovery of known Mproinhibitors such as calpain inhibitor II, as well as to the discovery of novel compounds that provide chemical information for future drug development efforts.
- Published
- 2024
- Full Text
- View/download PDF
9. Endogenous APOBEC3B overexpression characterizes HPV-positive and HPV-negative oral epithelial dysplasias and head and neck cancers
- Author
-
Argyris, Prokopios P., Wilkinson, Peter E., Jarvis, Matthew C., Magliocca, Kelly R., Patel, Mihir R., Vogel, Rachel I., Gopalakrishnan, Rajaram, Koutlas, Ioannis G., and Harris, Reuben S.
- Abstract
The DNA cytosine deaminase APOBEC3B (A3B) is a newly recognized endogenous source of mutations in a range of human tumors, including head/neck cancer. A3B inflicts C-to-T and C-to-G base substitutions in 5′-TCA/T trinucleotide motifs, contributes to accelerated rates of tumor development, and affects clinical outcomes in a variety of cancer types. High-risk human papillomavirus (HPV) infection causes A3B overexpression, and HPV-positive cervical and head/neck cancers are among tumor types with the highest degree of APOBEC signature mutations. A3B overexpression in HPV-positive tumor types is caused by the viral E6/E7 oncoproteins and may be an early off-to-on switch in tumorigenesis. In comparison, less is known about the molecular mechanisms responsible for A3B overexpression in HPV-negative head/neck cancers. Here, we utilize an immunohistochemical approach to determine whether A3B is turned from off-to-on or if it undergoes a more gradual transition to overexpression in HPV-negative head/neck cancers. As positive controls, almost all HPV-positive oral epithelial dysplasias and oropharyngeal cancers showed high levels of nuclear A3B staining regardless of diagnosis. As negative controls, A3B levels were low in phenotypically normal epithelium adjacent to cancer and oral epithelial hyperplasias. Interestingly, HPV-negative and low-grade oral epithelial dysplasias showed intermediate A3B levels, while high-grade oral dysplasias showed high A3B levels similar to oral squamous cell carcinomas. A3B levels were highest in grade 2 and grade 3 oral squamous cell carcinomas. In addition, a strong positive association was found between nuclear A3B and Ki67 scores suggesting a linkage to the cell cycle. Overall, these results support a model in which gradual activation of A3B expression occurs during HPV-negative tumor development and suggest that A3B overexpression may provide a marker for advanced grade oral dysplasia and cancer.
- Published
- 2021
- Full Text
- View/download PDF
10. Acute expression of human APOBEC3B in mice results in RNA editing and lethality
- Author
-
Alonso de la Vega, Alicia, Temiz, Nuri Alpay, Tasakis, Rafail, Somogyi, Kalman, Salgueiro, Lorena, Zimmer, Eleni, Ramos, Maria, Diaz-Jimenez, Alberto, Chocarro, Sara, Fernández-Vaquero, Mirian, Stefanovska, Bojana, Reuveni, Eli, Ben-David, Uri, Stenzinger, Albrecht, Poth, Tanja, Heikenwälder, Mathias, Papavasiliou, Nina, Harris, Reuben S., and Sotillo, Rocio
- Abstract
Background: RNA editing has been described as promoting genetic heterogeneity, leading to the development of multiple disorders, including cancer. The cytosine deaminase APOBEC3B is implicated in tumor evolution through DNA mutation, but whether it also functions as an RNA editing enzyme has not been studied. Results: Here, we engineer a novel doxycycline-inducible mouse model of human APOBEC3B-overexpression to understand the impact of this enzyme in tissue homeostasis and address a potential role in C-to-U RNA editing. Elevated and sustained levels of APOBEC3B lead to rapid alteration of cellular fitness, major organ dysfunction, and ultimately lethality in mice. Importantly, RNA-sequencing of mouse tissues expressing high levels of APOBEC3B identifies frequent UCC-to-UUC RNA editing events that are not evident in the corresponding genomic DNA. Conclusions: This work identifies, for the first time, a new deaminase-dependent function for APOBEC3B in RNA editing and presents a preclinical tool to help understand the emerging role of APOBEC3B as a driver of carcinogenesis.
- Published
- 2023
- Full Text
- View/download PDF
11. Human APOBEC3B promotes tumor development in vivoincluding signature mutations and metastases
- Author
-
Durfee, Cameron, Temiz, Nuri Alpay, Levin-Klein, Rena, Argyris, Prokopios P., Alsøe, Lene, Carracedo, Sergio, Alonso de la Vega, Alicia, Proehl, Joshua, Holzhauer, Anna M., Seeman, Zachary J., Liu, Xingyu, Lin, Yu-Hsiu T., Vogel, Rachel I., Sotillo, Rocio, Nilsen, Hilde, and Harris, Reuben S.
- Abstract
The antiviral DNA cytosine deaminase APOBEC3B has been implicated as a source of mutation in many cancers. However, despite years of work, a causal relationship has yet to be established in vivo. Here, we report a murine model that expresses tumor-like levels of human APOBEC3B. Animals expressing full-body APOBEC3B appear to develop normally. However, adult males manifest infertility, and older animals of both sexes show accelerated rates of carcinogenesis, visual and molecular tumor heterogeneity, and metastasis. Both primary and metastatic tumors exhibit increased frequencies of C-to-T mutations in TC dinucleotide motifs consistent with the established biochemical activity of APOBEC3B. Enrichment for APOBEC3B-attributable single base substitution mutations also associates with elevated levels of insertion-deletion mutations and structural variations. APOBEC3B catalytic activity is required for all of these phenotypes. Together, these studies provide a cause-and-effect demonstration that human APOBEC3B is capable of driving both tumor initiation and evolution in vivo.
- Published
- 2023
- Full Text
- View/download PDF
12. Determinants of Oligonucleotide Selectivity of APOBEC3B
- Author
-
Wagner, Jeffrey R., Demir, Özlem, Carpenter, Michael A., Aihara, Hideki, Harki, Daniel A., Harris, Reuben S., and Amaro, Rommie E.
- Abstract
APOBEC3B (A3B) is a prominent source of mutation in many cancers. To date, it has been difficult to capture the native protein–DNA interactions that confer A3B’s substrate specificity by crystallography due to the highly dynamic nature of wild-type A3B active site. We use computational tools to restore a recent crystal structure of a DNA-bound A3B C-terminal domain mutant construct to its wild type sequence, and run molecular dynamics simulations to study its substrate recognition mechanisms. Analysis of these simulations reveal dynamics of the native A3Bctd-oligonucleotide interactions, including the experimentally inaccessible loop 1-oligonucleotide interactions. A second series of simulations in which the target cytosine nucleotide was computationally mutated from a deoxyribose to a ribose show a change in sugar ring pucker, leading to a rearrangement of the binding site and revealing a potential intermediate in the binding pathway. Finally, apo simulations of A3B, starting from the DNA-bound open state, experience a rapid and consistent closure of the binding site, reaching conformations incompatible with substrate binding. This study reveals a more realistic and dynamic view of the wild type A3B binding site and provides novel insights for structure-guided design efforts for A3B.
- Published
- 2019
- Full Text
- View/download PDF
13. Inhibiting APOBEC3 Activity with Single-Stranded DNA Containing 2′-Deoxyzebularine Analogues
- Author
-
Kvach, Maksim V., Barzak, Fareeda M., Harjes, Stefan, Schares, Henry A. M., Jameson, Geoffrey B., Ayoub, Alex M., Moorthy, Ramkumar, Aihara, Hideki, Harris, Reuben S., Filichev, Vyacheslav V., Harki, Daniel A., and Harjes, Elena
- Abstract
APOBEC3 enzymes form part of the innate immune system by deaminating cytosine to uracil in single-stranded DNA (ssDNA) and thereby preventing the spread of pathogenic genetic information. However, APOBEC mutagenesis is also exploited by viruses and cancer cells to increase rates of evolution, escape adaptive immune responses, and resist drugs. This raises the possibility of APOBEC3 inhibition as a strategy for augmenting existing antiviral and anticancer therapies. Here we show that, upon incorporation into short ssDNAs, the cytidine nucleoside analogue 2′-deoxyzebularine (dZ) becomes capable of inhibiting the catalytic activity of selected APOBEC variants derived from APOBEC3A, APOBEC3B, and APOBEC3G, supporting a mechanism in which ssDNA delivers dZ to the active site. Multiple experimental approaches, including isothermal titration calorimetry, fluorescence polarization, protein thermal shift, and nuclear magnetic resonance spectroscopy assays, demonstrate nanomolar dissociation constants and low micromolar inhibition constants. These dZ-containing ssDNAs constitute the first substrate-like APOBEC3 inhibitors and, together, comprise a platform for developing nucleic acid-based inhibitors with cellular activity.
- Published
- 2019
- Full Text
- View/download PDF
14. Computational Model and Dynamics of Monomeric Full-Length APOBEC3G
- Author
-
Gorle, Suresh, Pan, Yangang, Sun, Zhiqiang, Shlyakhtenko, Luda S., Harris, Reuben S., Lyubchenko, Yuri L., and Vuković, Lela
- Abstract
APOBEC3G (A3G) is a restriction factor that provides innate immunity against HIV-1 in the absence of viral infectivity factor (Vif) protein. However, structural information about A3G, which can aid in unraveling the mechanisms that govern its interactions and define its antiviral activity, remains unknown. Here, we built a computer model of a full-length A3G using docking approaches and molecular dynamics simulations, based on the available X-ray and NMR structural data for the two protein domains. The model revealed a large-scale dynamics of the A3G monomer, as the two A3G domains can assume compact forms or extended dumbbell type forms with domains visibly separated from each other. To validate the A3G model, we performed time-lapse high-speed atomic force microscopy (HS-AFM) experiments enabling us to get images of a fully hydrated A3G and to directly visualize its dynamics. HS-AFM confirmed that A3G exists in two forms, a globular form (∼84% of the time) and a dumbbell form (∼16% of the time), and can dynamically switch from one form to the other. The obtained HS-AFM results are in line with the computer modeling, which demonstrates a similar distribution between two forms. Furthermore, our simulations capture the complete process of A3G switching from the DNA-bound state to the closed state. The revealed dynamic nature of monomeric A3G could aid in target recognition including scanning for cytosine locations along the DNA strand and in interactions with viral RNA during packaging into HIV-1 particles.
- Published
- 2017
- Full Text
- View/download PDF
15. Nanoscale Characterization of Interaction of APOBEC3G with RNA
- Author
-
Pan, Yangang, Sun, Zhiqiang, Maiti, Atanu, Kanai, Tapan, Matsuo, Hiroshi, Li, Ming, Harris, Reuben S., Shlyakhtenko, Luda S., and Lyubchenko, Yuri L.
- Abstract
The human cytidine deaminase APOBEC3G (A3G) is a potent inhibitor of the HIV-1 virus in the absence of viral infectivity factor (Vif). The molecular mechanism of A3G antiviral activity is primarily attributed to deamination of single-stranded DNA (ssDNA); however, the nondeamination mechanism also contributes to HIV-1 restriction. The interaction of A3G with ssDNA and RNA is required for its antiviral activity. Here we used atomic force microscopy to directly visualize A3G–RNA and A3G–ssDNA complexes and compare them to each other. Our results showed that A3G in A3G–RNA complexes exists primarily in monomeric–dimeric states, similar to its stoichiometry in complexes with ssDNA. New A3G–RNA complexes in which A3G binds to two RNA molecules were identified. These data suggest the existence of two separate RNA binding sites on A3G. Such complexes were not observed with ssDNA substrates. Time-lapse high-speed atomic force microscopy was applied to characterize the dynamics of the complexes. The data revealed that the two RNA binding sites have different affinities for A3G. On the basis of the obtained results, a model for the interaction of A3G with RNA is proposed.
- Published
- 2017
- Full Text
- View/download PDF
16. Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B
- Author
-
Shi, Ke, Carpenter, Michael A, Banerjee, Surajit, Shaban, Nadine M, Kurahashi, Kayo, Salamango, Daniel J, McCann, Jennifer L, Starrett, Gabriel J, Duffy, Justin V, Demir, Özlem, Amaro, Rommie E, Harki, Daniel A, Harris, Reuben S, and Aihara, Hideki
- Abstract
APOBEC-catalyzed cytosine-to-uracil deamination of single-stranded DNA (ssDNA) has beneficial functions in immunity and detrimental effects in cancer. APOBEC enzymes have intrinsic dinucleotide specificities that impart hallmark mutation signatures. Although numerous structures have been solved, mechanisms for global ssDNA recognition and local target-sequence selection remain unclear. Here we report crystal structures of human APOBEC3A and a chimera of human APOBEC3B and APOBEC3A bound to ssDNA at 3.1-Å and 1.7-Å resolution, respectively. These structures reveal a U-shaped DNA conformation, with the specificity-conferring −1 thymine flipped out and the target cytosine inserted deep into the zinc-coordinating active site pocket. The −1 thymine base fits into a groove between flexible loops and makes direct hydrogen bonds with the protein, accounting for the strong 5′-TC preference. These findings explain both conserved and unique properties among APOBEC family members, and they provide a basis for the rational design of inhibitors to impede the evolvability of viruses and tumors.
- Published
- 2017
- Full Text
- View/download PDF
17. Studies on antiviral resistant SARS-CoV-2 Mpro mutants
- Author
-
Esler, Morgan A., Moghadasi, Arad, Harris, Reuben S., and Aihara, Hideki
- Published
- 2023
- Full Text
- View/download PDF
18. SARS-CoV-2 3CLpromutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
- Author
-
Heilmann, Emmanuel, Costacurta, Francesco, Moghadasi, Seyed Arad, Ye, Chengjin, Pavan, Matteo, Bassani, Davide, Volland, Andre, Ascher, Claudia, Weiss, Alexander Kurt Hermann, Bante, David, Harris, Reuben S., Moro, Stefano, Rupp, Bernhard, Martinez-Sobrido, Luis, and von Laer, Dorothee
- Abstract
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first protease inhibitor specifically developed against the SARS-CoV-2 protease 3CLprothat has been licensed for clinical use. To identify mutations that confer resistance to this protease inhibitor, we engineered a chimeric vesicular stomatitis virus (VSV) that expressed a polyprotein composed of the VSV glycoprotein (G), the SARS-CoV-2 3CLpro, and the VSV polymerase (L). Viral replication was thus dependent on the autocatalytic processing of this precursor protein by 3CLproand release of the functional viral proteins G and L, and replication of this chimeric VSV was effectively inhibited by nirmatrelvir. Using this system, we applied nirmatrelvir to select for resistance mutations. Resistance was confirmed by retesting nirmatrelvir against the selected mutations in additional VSV-based systems, in an independently developed cellular system, in a biochemical assay, and in a recombinant SARS-CoV-2 system. We demonstrate that some mutants are cross-resistant to ensitrelvir and GC376, whereas others are less resistant to these compounds. Furthermore, we found that most of these resistance mutations already existed in SARS-CoV-2 sequences that have been deposited in the NCBI and GISAID databases, indicating that these mutations were present in circulating SARS-CoV-2 strains.
- Published
- 2023
- Full Text
- View/download PDF
19. Single-Molecule Force Spectroscopy Studies of APOBEC3A–Single-Stranded DNA Complexes
- Author
-
Shlyakhtenko, Luda S., Dutta, Samrat, Li, Ming, Harris, Reuben S., and Lyubchenko, Yuri L.
- Abstract
APOBEC3A (A3A) inhibits the replication of a range of viruses and transposons and might also play a role in carcinogenesis. It is a single-domain deaminase enzyme that interacts with single-stranded DNA (ssDNA) and converts cytidines to uridines within specific trinucleotide contexts. Although there is abundant information that describes the potential biological activities of A3A, the interplay between binding ssDNA and sequence-specific deaminase activity remains controversial. Using a single-molecule atomic force microscopy spectroscopy approach developed by Shlyakhtenko et al. [(2015) Sci. Rep. 5, 15648], we determine the stability of A3A in complex with different ssDNA sequences. We found that the strength of the complex is sequence-dependent, with more stable complexes formed with deaminase-specific sequences. A correlation between the deaminase activity of A3A and the complex strength was identified. The ssDNA binding properties of A3A and those for A3G are also compared and discussed.
- Published
- 2016
- Full Text
- View/download PDF
20. The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches
- Author
-
Richards, Christopher, Albin, John S., Demir, Özlem, Shaban, Nadine M., Luengas, Elizabeth M., Land, Allison M., Anderson, Brett D., Holten, John R., Anderson, John S., Harki, Daniel A., Amaro, Rommie E., and Harris, Reuben S.
- Abstract
APOBEC3 family DNA cytosine deaminases provide overlapping defenses against pathogen infections. However, most viruses have elaborate evasion mechanisms such as the HIV-1 Vif protein, which subverts cellular CBF-β and a polyubiquitin ligase complex to neutralize these enzymes. Despite advances in APOBEC3 and Vif biology, a full understanding of this direct host-pathogen conflict has been elusive. We combine virus adaptation and computational studies to interrogate the APOBEC3F-Vif interface and build a robust structural model. A recurring compensatory amino acid substitution from adaptation experiments provided an initial docking constraint, and microsecond molecular dynamic simulations optimized interface contacts. Virus infectivity experiments validated a long-lasting electrostatic interaction between APOBEC3F E289 and HIV-1 Vif R15. Taken together with mutagenesis results, we propose a wobble model to explain how HIV-1 Vif has evolved to bind different APOBEC3 enzymes and, more generally, how pathogens may evolve to escape innate host defenses.
- Published
- 2015
- Full Text
- View/download PDF
21. Lineage-Specific Viral Hijacking of Non-canonical E3 Ubiquitin Ligase Cofactors in the Evolution of Vif Anti-APOBEC3 Activity
- Author
-
Kane, Joshua R., Stanley, David J., Hultquist, Judd F., Johnson, Jeffrey R., Mietrach, Nicole, Binning, Jennifer M., Jónsson, Stefán R., Barelier, Sarah, Newton, Billy W., Johnson, Tasha L., Franks-Skiba, Kathleen E., Li, Ming, Brown, William L., Gunnarsson, Hörður I., Adalbjornsdóttir, Adalbjorg, Fraser, James S., Harris, Reuben S., Andrésdóttir, Valgerður, Gross, John D., and Krogan, Nevan J.
- Abstract
HIV-1 encodes the accessory protein Vif, which hijacks a host Cullin-RING ubiquitin ligase (CRL) complex as well as the non-canonical cofactor CBFβ, to antagonize APOBEC3 antiviral proteins. Non-canonical cofactor recruitment to CRL complexes by viral factors, to date, has only been attributed to HIV-1 Vif. To further study this phenomenon, we employed a comparative approach combining proteomic, biochemical, structural, and virological techniques to investigate Vif complexes across the lentivirus genus, including primate (HIV-1 and simian immunodeficiency virus macaque [SIVmac]) and non-primate (FIV, BIV, and MVV) viruses. We find that CBFβ is completely dispensable for the activity of non-primate lentiviral Vif proteins. Furthermore, we find that BIV Vif requires no cofactor and that MVV Vif requires a novel cofactor, cyclophilin A (CYPA), for stable CRL complex formation and anti-APOBEC3 activity. We propose modular conservation of Vif complexes allows for potential exaptation of functions through the acquisition of non-CRL-associated host cofactors while preserving anti-APOBEC3 activity.
- Published
- 2015
- Full Text
- View/download PDF
22. Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination
- Author
-
Lackey, Lela, Law, Emily K., Brown, William L., and Harris, Reuben S.
- Abstract
Humans have seven APOBEC3 DNA cytosine deaminases. The activity of these enzymes allows them to restrict a variety of retroviruses and retrotransposons, but may also cause pro-mutagenic genomic uracil lesions. During interphase the APOBEC3 proteins have different subcellular localizations: cell-wide, cytoplasmic or nuclear. This implies that only a subset of APOBEC3s have contact with nuclear DNA. However, during mitosis, the nuclear envelope breaks down and cytoplasmic proteins may enter what was formerly a privileged zone. To address the hypothesis that all APOBEC3 proteins have access to genomic DNA, we analyzed the localization of the APOBEC3 proteins during mitosis. We show that APOBEC3A, APOBEC3C and APOBEC3H are excluded from condensed chromosomes, but become cell-wide during telophase. However, APOBEC3B, APOBEC3D, APOBEC3F and APOBEC3G are excluded from chromatin throughout mitosis. After mitosis, APOBEC3B becomes nuclear, and APOBEC3D, APOBEC3F and APOBEC3G become cytoplasmic. Both structural motifs as well as size may be factors in regulating chromatin exclusion. Deaminase activity was not dependent on cell cycle phase. We also analyzed APOBEC3-induced cell cycle perturbations as a measure of each enzyme’s capacity to inflict genomic DNA damage. AID, APOBEC3A and APOBEC3B altered the cell cycle profile, and, unexpectedly, APOBEC3D also caused changes. We conclude that several APOBEC3 family members have access to the nuclear compartment and can impede the cell cycle, most likely through DNA deamination and the ensuing DNA damage response. Such genomic damage may contribute to carcinogenesis, as demonstrated by AID in B cell cancers and, recently, APOBEC3B in breast cancers.
- Published
- 2013
- Full Text
- View/download PDF
23. APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair
- Author
-
Nowarski, Roni, Wilner, Ofer I., Cheshin, Ori, Shahar, Or D., Kenig, Edan, Baraz, Leah, Britan-Rosich, Elena, Nagler, Arnon, Harris, Reuben S., Goldberg, Michal, Willner, Itamar, and Kotler, Moshe
- Abstract
APOBEC3 proteins catalyze deamination of cytidines in single-stranded DNA (ssDNA), providing innate protection against retroviral replication by inducing deleterious dC > dU hypermutation of replication intermediates. APOBEC3G expression is induced in mitogen-activated lymphocytes; however, no physiologic role related to lymphoid cell proliferation has yet to be determined. Moreover, whether APOBEC3G cytidine deaminase activity transcends to processing cellular genomic DNA is unknown. Here we show that lymphoma cells expressing high APOBEC3G levels display efficient repair of genomic DNA double-strand breaks (DSBs) induced by ionizing radiation and enhanced survival of irradiated cells. APOBEC3G transiently accumulated in the nucleus in response to ionizing radiation and was recruited to DSB repair foci. Consistent with a direct role in DSB repair, inhibition of APOBEC3G expression or deaminase activity resulted in deficient DSB repair, whereas reconstitution of APOBEC3G expression in leukemia cells enhanced DSB repair. APOBEC3G activity involved processing of DNA flanking a DSB in an integrated reporter cassette. Atomic force microscopy indicated that APOBEC3G multimers associate with ssDNA termini, triggering multimer disassembly to multiple catalytic units. These results identify APOBEC3G as a prosurvival factor in lymphoma cells, marking APOBEC3G as a potential target for sensitizing lymphoma to radiation therapy.
- Published
- 2012
- Full Text
- View/download PDF
24. First-In-Class Small Molecule Inhibitors of the Single-Strand DNA Cytosine Deaminase APOBEC3G
- Author
-
Li, Ming, Shandilya, Shivender M. D., Carpenter, Michael A., Rathore, Anurag, Brown, William L., Perkins, Angela L., Harki, Daniel A., Solberg, Jonathan, Hook, Derek J., Pandey, Krishan K., Parniak, Michael A., Johnson, Jeffrey R., Krogan, Nevan J., Somasundaran, Mohan, Ali, Akbar, Schiffer, Celia A., and Harris, Reuben S.
- Abstract
APOBEC3G is a single-stranded DNA cytosine deaminase that comprises part of the innate immune response to viruses and transposons. Although APOBEC3G is the prototype for understanding the larger mammalian polynucleotide deaminase family, no specific chemical inhibitors exist to modulate its activity. High-throughput screening identified 34 compounds that inhibit APOBEC3G catalytic activity. Twenty of 34 small molecules contained catechol moieties, which are known to be sulfhydryl reactive following oxidation to the orthoquinone. Located proximal to the active site, C321 was identified as the binding site for the inhibitors by a combination of mutational screening, structural analysis, and mass spectrometry. Bulkier substitutions C321-to-L, F, Y, or W mimicked chemical inhibition. A strong specificity for APOBEC3G was evident, as most compounds failed to inhibit the related APOBEC3A enzyme or the unrelated enzymes E. coliuracil DNA glycosylase, HIV-1 RNase H, or HIV-1 integrase. Partial, but not complete, sensitivity could be conferred to APOBEC3A by introducing the entire C321 loop from APOBEC3G. Thus, a structural model is presented in which the mechanism of inhibition is both specific and competitive, by binding a pocket adjacent to the APOBEC3G active site, reacting with C321, and blocking access to substrate DNA cytosines.
- Published
- 2012
- Full Text
- View/download PDF
25. Identification of Previously Unrecognized Multiple Myeloma Risk Subgroups with a Novel Biological Disease Stratifier
- Author
-
M. Shariatpanahi, Afsaneh, Grasedieck, Sarah, Jarvis, Matthew C., Borzooee, Faezeh, Harris, Reuben S., Larijani, Mani, Song, Kevin, Rouhi, Arefeh, and Kuchenbauer, Florian
- Abstract
Background:The prognosis of MM is determined by affected organs, tumor burden as measured by e.g., the international staging system (ISS), disease biology such as cytogenetic abnormalities, and response to therapy. The outcome of high-risk MM patients classified by ISS or adverse risk cytogenetics is not uniform and patients show heterogeneous survival. Recent insights into the pathogenesis of MM highlighted genome/transcriptome editing as well as inflammation as drivers for the onset and progression of MM. We hypothesized that inclusion of molecular features into risk stratification could potentially resolve the challenge of accurately distinguishing between high-risk and low-risk MM patients at initial diagnosis and improve outcome.
- Published
- 2021
- Full Text
- View/download PDF
26. Epstein-Barr Virus and the Somatic Hypermutation of Immunoglobulin Genes in Burkitt's Lymphoma Cells
- Author
-
Harris, Reuben S., Croom-Carter, Debbie S. G., Rickinson, Alan B., and Neuberger, Michael S.
- Abstract
ABSTRACTIt has been suggested that Epstein-Barr virus (EBV) might suppress antibody maturation either by facilitating bypass of the germinal center reaction or by inhibiting hypermutation directly. However, by infecting the Burkitt's lymphoma (BL) cell line Ramos, which hypermutates constitutively and can be considered a transformed analogue of a germinal center B cell, with EBV as well as by transfecting it with selected EBV latency genes, we demonstrate that expression of EBV gene products does not lead to an inhibition of hypermutation. Moreover, we have identified two natural EBV-positive BL cell lines (ELI-BL and BL16) that hypermutate constitutively. Thus, contrary to expectations, EBV gene products do not appear to affect somatic hypermutation.
- Published
- 2001
- Full Text
- View/download PDF
27. Somatic hypermutation and the three R's: repair, replication and recombination1Manuscript invited by Susan M. Rosenberg.1
- Author
-
Harris, Reuben S, Kong, Qingzhong, and Maizels, Nancy
- Abstract
Somatic hypermutation introduces single base changes into the rearranged variable (V) regions of antigen activated B cells at a rate of approximately 1 mutation per kilobase per generation. This is nearly a million-fold higher than the typical mutation rate in a mammalian somatic cell. Rampant mutation at this level could have a devastating effect, but somatic hypermutation is accurately targeted and tightly regulated. Here, we provide an overview of immunoglobulin gene somatic hypermutation; discuss mechanisms of mutation in model organisms that may be relevant to the hypermutation mechanism; and review recent advances toward understanding the possible role(s) of DNA repair, replication, and recombination in this fascinating process.
- Published
- 1999
- Full Text
- View/download PDF
28. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo
- Author
-
Law, Emily K., Levin-Klein, Rena, Jarvis, Matthew C., Kim, Hyoung, Argyris, Prokopios P., Carpenter, Michael A., Starrett, Gabriel J., Temiz, Nuri A., Larson, Lindsay K., Durfee, Cameron, Burns, Michael B., Vogel, Rachel I., Stavrou, Spyridon, Aguilera, Alexya N., Wagner, Sandra, Largaespada, David A., Starr, Timothy K., Ross, Susan R., and Harris, Reuben S.
- Abstract
The APOBEC3 family of antiviral DNA cytosine deaminases is implicated as the second largest source of mutation in cancer. This mutational process may be a causal driver or inconsequential passenger to the overall tumor phenotype. We show that human APOBEC3A expression in murine colon and liver tissues increases tumorigenesis. All other APOBEC3 family members, including APOBEC3B, fail to promote liver tumor formation. Tumor DNA sequences from APOBEC3A-expressing animals display hallmark APOBEC signature mutations in TCA/T motifs. Bioinformatic comparisons of the observed APOBEC3A mutation signature in murine tumors, previously reported APOBEC3A and APOBEC3B mutation signatures in yeast, and reanalyzed APOBEC mutation signatures in human tumor datasets support cause-and-effect relationships for APOBEC3A-catalyzed deamination and mutagenesis in driving multiple human cancers.
- Published
- 2020
- Full Text
- View/download PDF
29. HIV-1 Vif Triggers Cell Cycle Arrest by Degrading Cellular PPP2R5 Phospho-regulators
- Author
-
Salamango, Daniel J., Ikeda, Terumasa, Moghadasi, Seyed Arad, Wang, Jiayi, McCann, Jennifer L., Serebrenik, Artur A., Ebrahimi, Diako, Jarvis, Matthew C., Brown, William L., and Harris, Reuben S.
- Abstract
HIV-1 Vif hijacks a cellular ubiquitin ligase complex to degrade antiviral APOBEC3 enzymes and PP2A phosphatase regulators (PPP2R5A–E). APOBEC3 counteraction is essential for viral pathogenesis. However, Vif also functions through an unknown mechanism to induce G2 cell cycle arrest. Here, deep mutagenesis is used to define the Vif surface required for PPP2R5 degradation and isolate a panel of separation-of-function mutants (PPP2R5 degradation-deficient and APOBEC3G degradation-proficient). Functional studies with Vif and PPP2R5 mutants were combined to demonstrate that PPP2R5 is, in fact, the target Vif degrades to induce G2 arrest. Pharmacologic and genetic approaches show that direct modulation of PP2A function or depletion of specific PPP2R5 proteins causes an indistinguishable arrest phenotype. Vif function in the cell cycle checkpoint is present in common HIV-1 subtypes worldwide and likely advantageous for viral pathogenesis.
- Published
- 2019
- Full Text
- View/download PDF
30. Polyomavirus T Antigen Induces APOBEC3BExpression Using an LXCXE-Dependent and TP53-Independent Mechanism
- Author
-
Starrett, Gabriel J., Serebrenik, Artur A., Roelofs, Pieter A., McCann, Jennifer L., Verhalen, Brandy, Jarvis, Matthew C., Stewart, Teneale A., Law, Emily K., Krupp, Annabel, Jiang, Mengxi, Martens, John W. M., Cahir-McFarland, Ellen, Span, Paul N., and Harris, Reuben S.
- Abstract
The APOBEC3B DNA cytosine deaminase is overexpressed in many different cancers and correlates with elevated frequencies of C-to-T and C-to-G mutations in 5′-TC motifs, oncogene activation, acquired drug resistance, and poor clinical outcomes. The mechanisms responsible for APOBEC3B overexpression are not fully understood. Here, we show that the polyomavirus truncated T antigen (truncT) triggers APOBEC3B overexpression through its RB-interacting motif, LXCXE, which in turn likely modulates the binding of E2F family transcription factors to promote APOBEC3Bexpression. This work strengthens the mechanistic linkage between active cell cycling, APOBEC3B overexpression, and cancer mutagenesis. Although this mutational mechanism damages cellular genomes, viruses may leverage it to promote evolution, immune escape, and pathogenesis. The cellular portion of the mechanism may also be relevant to nonviral cancers, where genetic mechanisms often activate the RB/E2F axis and APOBEC3B mutagenesis contributes to tumor evolution.
- Published
- 2019
- Full Text
- View/download PDF
31. Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma
- Author
-
Starrett, Gabriel J., Marcelus, Christina, Cantalupo, Paul G., Katz, Joshua P., Cheng, Jingwei, Akagi, Keiko, Thakuria, Manisha, Rabinowits, Guilherme, Wang, Linda C., Symer, David E., Pipas, James M., Harris, Reuben S., and DeCaprio, James A.
- Abstract
ABSTRACTMerkel cell polyomavirus is the primary etiological agent of the aggressive skin cancer Merkel cell carcinoma (MCC). Recent studies have revealed that UV radiation is the primary mechanism for somatic mutagenesis in nonviral forms of MCC. Here, we analyze the whole transcriptomes and genomes of primary MCC tumors. Our study reveals that virus-associated tumors have minimally altered genomes compared to non-virus-associated tumors, which are dominated by UV-mediated mutations. Although virus-associated tumors contain relatively small mutation burdens, they exhibit a distinct mutation signature with observable transcriptionally biased kataegic events. In addition, viral integration sites overlap focal genome amplifications in virus-associated tumors, suggesting a potential mechanism for these events. Collectively, our studies indicate that Merkel cell polyomavirus is capable of hijacking cellular processes and driving tumorigenesis to the same severity as tens of thousands of somatic genome alterations.IMPORTANCEA variety of mutagenic processes that shape the evolution of tumors are critical determinants of disease outcome. Here, we sequenced the entire genome of virus-positive and virus-negative primary Merkel cell carcinomas (MCCs), revealing distinct mutation spectra and corresponding expression profiles. Our studies highlight the strong effect that Merkel cell polyomavirus has on the divergent development of viral MCC compared to the somatic alterations that typically drive nonviral tumorigenesis. A more comprehensive understanding of the distinct mutagenic processes operative in viral and nonviral MCCs has implications for the effective treatment of these tumors.
- Published
- 2017
- Full Text
- View/download PDF
32. The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches
- Author
-
Demir, Ozlem, Richards, Christopher, Albin, John S., Shaban, Nadine M., Anderson, Brett D., Amaro, Rommie E., and Harris, Reuben S.
- Published
- 2016
- Full Text
- View/download PDF
33. Human Papillomavirus E6 Triggers Upregulation of the Antiviral and Cancer Genomic DNA Deaminase APOBEC3B
- Author
-
Vieira, Valdimara C., Leonard, Brandon, White, Elizabeth A., Starrett, Gabriel J., Temiz, Nuri A., Lorenz, Laurel D., Lee, Denis, Soares, Marcelo A., Lambert, Paul F., Howley, Peter M., and Harris, Reuben S.
- Abstract
ABSTRACTSeveral recent studies have converged upon the innate immune DNA cytosine deaminase APOBEC3B (A3B) as a significant source of genomic uracil lesions and mutagenesis in multiple human cancers, including those of the breast, head/neck, cervix, bladder, lung, ovary, and other tissues. A3Bis upregulated in these tumor types relative to normal tissues, but the mechanism is unclear. Because A3B also has antiviral activity in multiple systems and is a member of the broader innate immune response, we tested the hypothesis that human papillomavirus (HPV) infection causes A3B upregulation. We found that A3BmRNA expression and enzymatic activity were upregulated following transfection of a high-risk HPV genome and that this effect was abrogated by inactivation of E6. Transduction experiments showed that the E6 oncoprotein alone was sufficient to cause A3Bupregulation, and a panel of high-risk E6 proteins triggered higher A3Blevels than did a panel of low-risk or noncancer E6 proteins. Knockdown experiments in HPV-positive cell lines showed that endogenous E6is required for A3Bupregulation. Analyses of publicly available head/neck cancer data further support this relationship, as A3Blevels are higher in HPV-positive cancers than in HPV-negative cancers. Taken together with the established role for high-risk E6 in functional inactivation of TP53 and published positive correlations in breast cancer between A3Bupregulation and genetic inactivation of TP53, our studies suggest a model in which high-risk HPV E6, possibly through functional inactivation of TP53, causes derepression of A3Bgene transcription. This would lead to a mutator phenotype that explains the observed cytosine mutation biases in HPV-positive head/neck and cervical cancers.IMPORTANCEThe innate immune DNA cytosine deaminase APOBEC3B (A3B) accounts for a large proportion of somatic mutations in cervical and head/neck cancers, but nothing is known about the mechanism responsible for its upregulation in these tumor types. Almost all cervical carcinomas and large proportions of head/neck tumors are caused by human papillomavirus (HPV) infection. Here, we establish a mechanistic link between HPV infection and A3Bupregulation. The E6 oncoprotein of high-risk, but not low-risk, HPV types triggers A3Bupregulation, supporting a model in which TP53 inactivation causes a derepression of A3Bgene transcription and elevated A3B enzyme levels. This virus-induced mutator phenotype provides a mechanistic explanation for A3B signature mutations observed in HPV-positive head/neck and cervical carcinomas and may also help to account for the preferential cancer predisposition caused by high-risk HPV isolates.
- Published
- 2014
- Full Text
- View/download PDF
34. Fluorescence Fluctuation Spectroscopy Applied to Cell-Free Expression, Chromophore Maturation and Protein-DNA Interaction
- Author
-
Macdonald, Patrick J., Chen, Yan, Li, Ming, Harris, Reuben S., and Mueller, Joachim D.
- Published
- 2012
- Full Text
- View/download PDF
35. O III A.3 Recombination-dependent stationary-phase mutation: A model for mutagenesis in non-dividing cells
- Author
-
Harris, Reuben S., Torkelson, Joel, Feng, Gang, Lombardo, Mary-Jane, Rose, Kimberly J., Longerich, Simonne, Nagendran, Jayan, Sidhu, Roger, Thulin, Carl, Szigety, Susan K., McKenzie, Gregory, Bull, Horold J., Winkler, Malcolm E., and Rosenberg, Susan M.
- Published
- 1997
- Full Text
- View/download PDF
36. Dancin' deaminase.
- Author
-
Harris RS and Matsuo H
- Subjects
- APOBEC-3G Deaminase, Cytidine Deaminase, Cytosine chemistry, Cytosine metabolism, Cytosine Deaminase metabolism, DNA genetics, DNA metabolism, Deamination, Humans, Mutation genetics, Nucleoside Deaminases genetics, Repressor Proteins genetics, Nucleoside Deaminases metabolism, Repressor Proteins metabolism
- Abstract
New biochemical experiments with the retroelement restriction protein APOBEC3G indicate that it processively deaminates single-stranded DNA cytosines by a unique jumping and sliding mechanism.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.